Case report

**Serum calcitonin negative Medullary thyroid carcinoma**

Michael Sand*1, Marcos Gelos1, Daniel Sand2, Falk G Bechara3, Gerd Bonhag1, Ellen Welsing1 and Benno Mann1

Address: 1Department of General and Visceral Surgery, Augusta Krankenanstalt, Academic Teaching Hospital, Ruhr-University Bochum, Germany, 2Department of Physiological Science, University of California Los Angeles (UCLA), California, USA and 3Department of Dermatology and Allergology, Ruhr-University Bochum, Germany

Email: Michael Sand* - michael.sand@ruhr-uni-bochum.de; Marcos Gelos - mgelos@gmx.de; Daniel Sand - ucla_daniel@yahoo.com; Falk G Bechara - bechara@web.de; Gerd Bonhag - bonhag@augusta-bochum.de; Ellen Welsing - welsing@augusta-bochum.de; Benno Mann - mann@augusta-bochum.de

* Corresponding author

**Abstract**

**Background:** Medullary thyroid carcinomas (MTC) constitute about 5 to 7% of thyroid neoplasms. They originate from parafollicular C cells which produce Calcitonin, a hormone which has an impact on calcium metabolism and represents the biochemical activity of MTC. In rare cases pre-operative serum calcitonin can be negative.

**Case presentation:** We report on a 73-year-old female patient with a rare case of a serum calcitonin negative medullary thyroid carcinoma who suffered fulminant post-operative course and died of multiple metastasis.

**Conclusion:** This case shows that in very rare cases MTCs do not secrete calcitonin making diagnosis and tumour follow-up difficult. To this date, only few reports describing this combination of circumstances were found in the English literature.

**Background**

Medullary thyroid carcinomas (MTC) constitute about 5 to 7% of thyroid neoplasms. They originate from parafollicular C cells which are derived from the ultimobranchial body and neural crest [1]. C cells produce Calcitonin, a hormone which has an impact on calcium metabolism. Microscopically the tumor is characterized by small nests of small, round cells, production of amyloid and dense irregular areas of calcification [1]. Cervical lymph node metastases occur early in the disease in about 50% of cases with distant metastases occurring later. Cervical metastases most commonly involve the central, paratracheal and jugular regions. Distant metastases favor the mediastinum, liver, lung and bone [2]. The incidence in male/female ratio is roughly equal over a wide age range. Most of MTC are sporadic and usually unilateral. Familial medullary carcinoma occurs in the multiple endocrine neoplasia syndromes (MEN) of the type 2 variety. When occurring in association with MEN syndromes it is usually bilateral and typically the first abnormality observed in both MEN 2A and 2B syndromes.

The biochemical activity of medullary thyroid carcinoma includes production of calcitonin and cacinoembryogenic antigen (CEA). In rare cases pre-operative serum calcitonin can be negative. To this date, only few reports describing this combination of circumstances were found in the English literature [3-5].
Case presentation

We report on a 73-year-old female patient with an 8-year history of thyroid nodules for which she underwent regular clinical examination and blood tests. Three weeks before referral to our endocrinological surgery unit she developed a swelling of her head and neck lymph nodes. Her past medical history included surgical removal of a benign breast tumor 22 years ago. Her family history was unremarkable regarding any endocrinological or thyroid disease. Besides her obesity she was suffering from reflux disease and hypertension. She had a regular pulse of 68/ per minute and blood pressure of 120/70 mmHg under antihypertensive medication. Her muscle tone was reduced. She had observed a change of her voice and had lost 20 kg of weight within the past 4 months. A thyroid scintigram showed multiple confluent cold nodules which were highly suspicious for malignant neoplasm of both thyroid lobes and regional lymph node metastases along both jugular veins. Clinical exam and sonography showed multiple enlarged lymph nodes of the head and neck. Pre-operative serum calcitonin was 5.3 pg/ml (normal range 0.8–9.9 pg/ml). Based on the history, clinical presentation and the scintigram we suspected an anaplastic thyroid carcinoma and performed a radical oncologic thyroidectomy with bilateral modified neck-dissection and resection of the right internal jugular vein and the left recurrent laryngeal nerve. Intraoperatively the tumor was tightly adherent to the surface of the trachea. Because of the impressing clinical picture a fine needle aspiration was not performed prior to surgery. In the authors' point of view it would have had no prognostic effect at this advanced stage of disease. A pre-operative pentagastrin test was also not performed as clinical presentation made the presence of an anaplastic carcinoma highly suspicious. Surprisingly, histopathology showed a pT3 L1 V1 R1 N1b low-differentiated medullary-thyroid carcinoma with massive lymphangiosis and haemangiosis carcinomatosa. Immunhistochemistry revealed weak positive staining for calcitonin and carcinoembryogenic antigen (CEA) (Figure 1). Post-operative serum calcitonin decreased to 2.47 pg/ml still being within normal range (0.8–9.9 pg/ml). Post operatively the patient was in the intensive care unit for 6 days. A pentagastrin stimulation test was not performed due to the bad condition of the patient. A permanent tracheostoma was established to ensure a patent airway as the patient aspirated after initial extubation. Additionally massive crust formation obstructed the patient's airway as which was treated with a humidifier and frequent irrigations with physiological saline solution and subsequent suctioning of the trachea. Unfortunately the patient developed central lung emboli in the right pulmonary artery. A postoperative CT scan showed multiple lung and intracerebral metastases (Figure 2 and Figure 3). The patient died six weeks after diagnosis.

Discussion

Medullary thyroid carcinoma is a rare calcitonin-secreting neoplasm that occurs in both a familial and sporadic form [6]. It is the most aggressive well differentiated thyroid carcinoma, with survival rates of 40–50 % at 10 years [7]. Routine measurements of serum calcitonin levels are considered to be an integral part of the diagnostic evaluation of thyroid nodules and the diagnosis of medullary thyroid carcinoma. It has been suggested that calcitonin testing, both with and without pentagastrin stimulation, may facilitate early diagnosis of this disease and ultimately decrease morbidity and mortality [8-12]. Serum CT is the most specific and sensitive marker of MTC for both the primary diagnosis and the postsurgical follow-up [13]; it is produced in abnormally high concentrations by almost 100 % of primary and metastatic MTCs. However in rare cases, as described here, serum calcitonin can be negative. Although our patient had a voluminous, rapidly growing medullary thyroid carcinoma with multiple metastases pre-operative serum calcitonin was within normal range. An calcitonin assay-specific problem is unlikely because different assays were used postoperatively (Nicols Advantage Chemiluminescence Assay, Nichols Institute Diagnostics Inc., San Clemente, CA, USA and Immulite Calcitonin Assay, DPC-Bühlmann GmbH, Salzburg, Austria). Before referral to our department the patient's thyroid nodules were monitored by annual checks of thyroid hormone and serum calcitonin. One would expect that the expression of an antigen in the neoplastic cells would be associated with the hypersecretion of the corresponding antigen in the circulation, as in the case of Calcitonin and CEA. The levels of these antigens are described to be elevated in patients with metastastatic medullary thyroid carcinoma and as accurate reflections of new metastases [12-15]. Regrettably this was not the case in our patient. It is possible that rare forms of MTC go along with mutations in the calcitonin/CGRP gene which might be responsible for the normal or relatively reduced calcitonin levels. It would be interesting to examine the calcitonin/CGRP gene structure in these patients. Analysis of white blood cell DNA by Southern blot hybridizations could show deletions or rearrangements in the calcitonin/CGRP gene locus. Additionally defects in the cellular machinery needed for calcitonin synthesis and/or secretion could be responsible. The tumour showed positivity for calcitonin in the immunohistochemistry which is in line with the latter hypothesis that calcitonin production is active but secretion mechanisms might be altered. Bockhorn et al. also reported a similar case of a 50 year old woman with a serum calcitonin negative MTC. Comparing the histologies we have observed some (uncharacteristic) similarities: the cells described were also relatively large with an increased caryoplasmic ratio, indistinct cell borders and partly spindled cytoplasm. It would be interesting to com-
pare the histologies of other serum calcitonin negative MTC’s which might show histomorphologic similarities.

This report illustrates that in rare cases the diagnosis of medullary thyroid carcinoma cannot be excluded by means of laboratory values such as serum calcitonin. When serum calcitonin is negative a cytomorphologic analysis of fine needle aspiration and a determination of RET proto-oncogene mutations are two diagnostic tools which are available for detection and accurate management of patients in whom medullary thyroid carcinoma is expected [16].

Conclusion
This case shows that in very rare cases MTCs do not secrete calcitonin making diagnosis and tumour follow-up difficult.

Conflict of interests
All authors hereby disclose any commercial associations which might pose or create a conflict of interest with information presented in this manuscript. All authors declare that they have no competing interests.

Authors’ contributions
MS: documented and prepared the draft

MG: Revised and edited most of the manuscript and helped in preparing the draft

DS: Literature search, revision of bibliography and helped with editing of the manuscript

FGB: Literature search and edited part of the manuscript
EW: Surgeon who performed the operations and helped in preparing the manuscript

GB: Surgeon who performed the operations and helped in preparing the manuscript

BM: Surgeon who performed the operations and edited part of the manuscript and helped in preparing the draft

All authors read and approved final manuscript.

Acknowledgements
The written consent was obtained from the patient for publication of this case report.

References
1. Cohen EG, Shaha AR, Rinaldo A, Devaney KO, Ferlito A: Medullary thyroid carcinoma. Acta Otolaryngol 2004, 124:544-557.
2. Shaha AR, Ferlito A, Rinaldo A: Distant metastases from thyroid and parathyroid cancer. ORL J Otorhinolaryngol Relat Spec 2001, 63:243-239.
3. Redding AH, Levine SN, Fowler MR: Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses. Thyroid 2000, 10:919-922.
4. Bockhorn M, Frilling A, Rework S, Liedke M, Dirsch O, Schmid KW, Broeelsch C. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma. Thyroid 2004, 14:468-470.
5. Bockhorn M, Frilling A, Rework S, Liedke M, Dirsch O, Schmid KW, Broeelsch C. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma. Thyroid 2004, 14:984-985.
6. Williams ED, Brown CL, Doniach I: Pathological and clinical findings in a series of 67 cases of medullary carcinoma of the thyroid. J Clin Pathol 1966, 19:103-113.
7. Gharib H, McConahey WM, Tiesgs RD, Bergstrahl EJ, Goellner JR, Grant CS, van Heerden JA, Sizemore GW, Hay ID: Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clin Proc 1992, 67:934-940.
8. Hahn JH, Lee MS, Min YK, Lee MK, Kim KW, Nam SJ, Yang JH, Chung JH: Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 2001, 11:73-80.
9. Ozgen AG, Hamulcu F, Bayraktar F, Yilmaz C, Tuzun M, Yetkin E, Tunçyurek M, Kabalak T: Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Thyroid 1999, 9:579-582.
10. Vierhapper H, Raber W, Biegalmayer C, Kaserer K, Weinhaas A, Niederle B: Routine measurement for plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 1997, 82:1589-1593.
11. Rieu M, Lame MC, Richard A, Lissak B, Sambort B, Vuong-Ngoc P, Berrod JL, Fombeur JP: Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clin Endocrinol 1995, 42:453-460.
12. Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C, Di Coscio G, Miccoli P, Pinchera A: Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected medullary thyroid carcinoma. J Clin Endocrinol Metab 1994, 78:826-829.
13. Tashjian AH Jr, Howland BG, Melvin KEW, Hill CS Jr: Immunoassay of human calcitonin. Clinical measurement, relation to serum calcium and studies in patients with medullary thyroid carcinoma. N Engl J Med 1970, 283:890-895.
14. Elisei R, Botocci V, Luchetti F, Di Coscio G, Romei C, Grassi L, Miccoli P, Iacconi P, Basolo F, Pinchera A, Pacini F: Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004, 89:163-168.
15. Papi G, Corsello SM, Cioni K, Pizzini AM, Corrado S, Carapezzi C, Fadda G, Baldini A, Carani C, Pontecorvi A, Rosi E: Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: A multicenter study. J Endocrinol Invest 2006, 29:427-437.
16. Chang TC, Wu SL, Huiao YL: Medullary thyroid carcinoma: pitfalls in diagnosis by fine needle aspiration cytology and relationship of cytormorphology to RET proto-oncogene mutations. Acta Cytol 2005, 49:477-482.

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp